XOMA acquired by Ligand
Ligand agreed to acquire XOMA, a biopharma brand, on Apr 27, 2026.
Preliminary: The announcement date is not yet independently verified.
Transaction summary
- Target
- XOMA
- Acquirer
- Ligand
- Seller
- -
- Announced
- 2026-04-27(unverified)
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-13
- Latest update
- 2026-10-29
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Enterprise value is unavailable.
Source summary
Biopharma bites: 'Green shoots' for UK's biotech sector, Ligand buys XOMA and more from AstraZeneca, Novartis - FirstWord Pharma
ConfirmedFirstWord Pharma item dated Apr. 27, 2026 is titled as biopharma news including Ligand buying XOMA; the page text itself was not accessible beyond a JavaScript loading notice.
Open sourceContinue your research
Related transaction comps
Celgene acquired by Bristol-Myers Squibb
- · Confirmed
View transaction → BiotechEdgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction → BiotechMyricx Bio acquired by Novartis
2026-07-06 · Confirmed
View transaction → BiotechBio-Techne acquired by Merck KGaA, Darmstadt, Germany
2026-06-25 · Confirmed
View transaction →